Academic Institutions and PIs

Researchers around the globe studying basic immunology and/or the complex manner in which cells of the adaptive immune system influence disease are using immunoSEQ.

Notably, many are already using immunoSEQ on a repeat basis as they begin to answer critical questions that they were previously unable to answer.

Members of the immunoSEQ community »

Biopharmaceutical Industry

Like researchers and investigators at academic institutions, clinical and biomarker teams at biopharmaceutical companies are also using the quantitative characterizations of the immune repertoire made available by immunoSEQ assays to ask and answer critical questions about disease diagnosis, progression, and treatment.

Research Networks/Cooperative Groups

The immunoSEQ technology has been selected as a core lab for the Immune Tolerance Network and discussions are underway for similar partnerships with other research networks.

The benefits to a disease-focused research network of selecting immunoSEQ as a core lab are many:

• Rigorous due diligence process (one-time)
• Potential to customize analytic tools
• Ability to generate cumulative longitudinal databases
• Potential to alter treatment paradigm for specific disease area

Adaptive Biotechnologies Scientists

Adaptive Biotechnologies scientists are also using the immunoSEQ assay to conduct primary research in several areas including pathogen exposure, stem cell transplantation, vaccine efficacy, monitoring minimal residual disease, and autoimmune diseases. To date, we have received 8 grants from the NIH and other prestigious institutions to conduct this research.

We anticipate a continued stream of publications highlighting key discoveries from our internal research and how these discoveries may inform further research and/or clinical outcomes.

To demo the immunoSEQ Analyzer, click here »